Skip to content
Immunophotonics
  • About
    • Team
    • Board of Directors
    • Advisory Board
    • Highlighted Co-Inventor
    • Collaborators
  • Technology
  • Interventional Immuno-Oncology®
  • Clinical Trials
    • Colorectal Cancer (CRC)
    • Non-Small Cell Lung Cancer (NSCLC)
    • Melanoma
    • Soft Tissue Sarcoma (STS)
    • Hepatocellular Carcinoma (HCC)
    • Pancreatic Cancer
    • Vaccine Adjuvant
  • Patients
  • News & Media
  • Contact Us
Menu

News

404

News & Media

  •          
  • Print
Home » News & Media
Latest News Press Releases

Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in France

September 25, 2023
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in a multinational clinical trial in France at…
Read More
Latest News

RESI Boston 2023 – September 18th

September 14, 2023
Immunophotonics Co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Boston attending the RESI Boston…
Read More
Latest News

CIRSE 2023 September 9 – 13, 2023

September 13, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be at Booth F18 at the CIRSE…
Read More
Latest News Press Releases

Immunophotonics Announces 1st Patient Treated in Germany

July 17, 2023
Immunophotonics, Inc. has announced the recruitment and dosing of its first patient in Germany at SLK Kliniken Heilbronn GmbH. The…
Read More
Latest News Press Releases

Immunophotonics Announces 1st Patient Dosed in Multinational Clinical Trial in the United Kingdom

June 1, 2023
Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the…
Read More
Latest News

SACHS Forum and ASCO Annual Meeting in Chicago June 2 – 6, 2023

June 1, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Chicago at the SACHS 9th…
Read More
Latest News Press Releases

Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S.

May 18, 2023
Immunophotonics has announced the FDA’s decision to allow the U.S. clinical trial of IP-001 to proceed with the enrollment of…
Read More
Latest News

Swiss Biotech Day 2023 April 24 & 25

April 20, 2023
Immunophotonics is pleased to announce its participation at the Swiss Biotech Day in Basel, Switzerland where VP of Business Development…
Read More
Latest News

European Conference on Interventional Oncology (ECIO 2023) April 16 – 19

April 12, 2023
Immunophotonics co-founders Lu Alleruzzo (CEO) and Tomas Hode, PhD (CIO and President) will be in Booth 10 at the European…
Read More
Latest News

Indian Patent Office Issues Patent Covering Immunophotonics’ Lead Drug Candidate, IP-001

April 5, 2023
Immunophotonics is excited to announce that its composition-of-matter patent has been granted by the Indian Patent Office (ISA/IPEA).  With this…
Read More
« Previous 1 … 7 8 9 10 11 … 14 Next »
Contact us for more info and updates
  • About
  • Team
  • Board of Directors
  • Advisory Board
  • Highlighted Co-Inventor
  • Collaborators
  • Technology
  • Clinical Trials
  • Colorectal Cancer (CRC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Melanoma
  • Soft Tissue Sarcoma (STS)
  • Hepatocellular Carcinoma (HCC)
  • Pancreatic Cancer
  • Vaccine Adjuvant
  • Patients
  • Background
  • Trial Summary

Quick Links

  • Interventional Immuno-Oncology®
  • News & Media
  • Careers
  • Contact Us
  • Privacy Policy
  • Site Map
© Immunophotonics, Inc. All Rights Reserved
Terms of Use | FCOI Policy
Website by Axxiem
Scroll to top